Scibase AB - Asset Resilience Ratio

Latest as of December 2025: 43.33%

Scibase AB (SCIB) has an Asset Resilience Ratio of 43.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Scibase AB (SCIB) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr22.60 Million
≈ $2.43 Million USD Cash + Short-term Investments

Total Assets

Skr52.17 Million
≈ $5.61 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Scibase AB's Asset Resilience Ratio has changed over time. See how leveraged is Scibase AB's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Scibase AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Scibase AB stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr22.60 Million 43.33%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr22.60 Million 43.33%

Asset Resilience Insights

  • Very High Liquidity: Scibase AB maintains exceptional liquid asset reserves at 43.33% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Scibase AB Industry Peers by Asset Resilience Ratio

Compare Scibase AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medacta Group SA
SW:MOVE
Medical Devices 0.86%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Xiangyu Medical Co. Ltd. A
SHG:688626
Medical Devices 1.53%
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 5.73%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%

Annual Asset Resilience Ratio for Scibase AB (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Scibase AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 43.33% Skr22.60 Million
≈ $2.43 Million
Skr52.17 Million
≈ $5.61 Million
+25.11pp
2024-12-31 18.22% Skr11.24 Million
≈ $1.21 Million
Skr61.73 Million
≈ $6.64 Million
-34.82pp
2023-12-31 53.04% Skr34.12 Million
≈ $3.67 Million
Skr64.33 Million
≈ $6.92 Million
+15.26pp
2022-12-31 37.77% Skr18.83 Million
≈ $2.03 Million
Skr49.85 Million
≈ $5.37 Million
-39.00pp
2021-12-31 76.77% Skr65.61 Million
≈ $7.06 Million
Skr85.46 Million
≈ $9.20 Million
+6.86pp
2020-12-31 69.92% Skr41.43 Million
≈ $4.46 Million
Skr59.25 Million
≈ $6.38 Million
+12.61pp
2019-12-31 57.31% Skr26.46 Million
≈ $2.85 Million
Skr46.16 Million
≈ $4.97 Million
-25.92pp
2018-12-31 83.23% Skr67.51 Million
≈ $7.27 Million
Skr81.11 Million
≈ $8.73 Million
-2.77pp
2017-12-31 86.01% Skr110.02 Million
≈ $11.84 Million
Skr127.91 Million
≈ $13.77 Million
+2.81pp
2016-12-31 83.20% Skr84.95 Million
≈ $9.14 Million
Skr102.11 Million
≈ $10.99 Million
+78.75pp
2012-12-31 4.45% Skr1.06 Million
≈ $114.31K
Skr23.87 Million
≈ $2.57 Million
--
pp = percentage points

About Scibase AB

ST:SCIB Sweden Medical Devices
Market Cap
$3.94 Billion
Skr36.61 Billion SEK
Market Cap Rank
#12819 Global
#199 in Sweden
Share Price
Skr35.80
Change (1 day)
-15.47%
52-Week Range
Skr0.21 - Skr50.80
All Time High
Skr50.80
About

SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more